HRMY

Harmony is a rare profitable single-product biopharma with genuinely high-quality economics: FY2025 revenue of $868M grew 21.5% on a five-year ramp ($305M→$868M since 2021), at a 77.2% gross margin, 24.0% operating margin and 18.3% net margin, producing $159M net income and 18.2% ROE. The balance sheet is fortress-like — $753M cash (+66%), liabilities/equity of just 0.46x, $144M long-term debt declining, and $348M operating cash flow (+58%) against trivial $310K capex. At $35.34 the stock trades at 13.0x FY diluted EPS of $2.71 and 2.4x sales; for a 20%+ top-line grower throwing off this much cash, that is an undemanding multiple that prices in much of the bear case already.

The central, self-disclosed risk is concentration: management states it is 'substantially dependent on the commercial success of our only approved product, WAKIX,' and that revenue depends on payor reimbursement, market acceptance, and — critically — 'potential competition from generic versions of pitolisant.' The numbers show the margin cost of defending and extending that single franchise: net income grew only 9.1% and EPS 8.0% versus 21.5% revenue growth, as R&D jumped 30% to $190M and operating income rose just 9.2%. So this is not a clean compounder — earnings leverage is being deliberately reinvested into the pipeline, and the durability of the WAKIX cash cow ultimately hinges on patents/IP holding off generics.